For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Vera Therapeutics Inc (NASDAQ: VERA) closed at $32.00 in the last session, up 3.51% from day before closing price of $30.91. In other words, the price has increased by $3.51 from its previous closing price. On the day, 2.52 million shares were traded.
Ratios:
We take a closer look at VERA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 27.30 and its Current Ratio is at 27.30. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $49.
On January 28, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $58.Goldman initiated its Buy rating on January 28, 2025, with a $58 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 21 ’25 when Fordyce Marshall sold 10,613 shares for $27.89 per share. The transaction valued at 296,032 led to the insider holds 213,740 shares of the business.
Fordyce Marshall sold 9,075 shares of VERA for $250,882 on Feb 26 ’25. The PRESIDENT AND CEO now owns 204,665 shares after completing the transaction at $27.65 per share. On Feb 26 ’25, another insider, MARSHALL FORDYCE, who serves as the Director of the company, bought 9,075 shares for $27.10 each.
Stock Price History:
Over the past 52 weeks, VERA has reached a high of $51.61, while it has fallen to a 52-week low of $18.53. The 50-Day Moving Average of the stock is 40.72%, while the 200-Day Moving Average is calculated to be -8.65%.
Shares Statistics:
A total of 63.77M shares are outstanding, with a floating share count of 48.07M. Insiders hold about 24.63% of the company’s shares, while institutions hold 90.09% stake in the company.
Earnings Estimates
The current rating of Vera Therapeutics Inc (VERA) is the result of assessments by 7.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.83, with high estimates of -$0.66 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$2.79 and -$3.86 for the fiscal current year, implying an average EPS of -$3.35. EPS for the following year is -$2.98, with 5.0 analysts recommending between -$2.28 and -$3.74.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $37.08M in the next fiscal year. The high estimate is $81.7M and the low estimate is $26.3M.
